Combined and Simultaneous Approach for the Treatment of High-risk Gastric Varices Using B-RTO and EVO
- Conditions
- Gastric Varices BleedingGastric Varix
- Interventions
- Procedure: balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices
- Registration Number
- NCT03853720
- Lead Sponsor
- Centre Hospitalier Universitaire Vaudois
- Brief Summary
The aim of this pilot study is to evaluate the efficacy and safety of combined and simultaneous endoscopic variceal obliteration together with balloon occluded-retrograde transvenous obliteration (B-RTO) for the treatment of high-risk gastric varices
- Detailed Description
Although less frequent than esophageal varices, gastric varices constitute a severe and potentially life threatening complication of portal hypertension. Various methods have been described to treat gastric varices, including endoscopic and interventional radiology techniques. Endoscopic variceal obliteration (EVO) is currently considered as standard of care for the treatment of gastric varices in most centers. However, this technique is associated with significant rebleeding rates and incomplete obliteration is observed in about 50% of patients. Alternatively, few centers also use an interventional radiology technique, called balloon-occluded retrograde transvenous obliteration (B-RTO) to treat gastric varices, which has been shown to be associated with less recurrence of gastric varices and high rates of eradication of about 90%. Both techniques have their inherent weaknesses, such as frequent incomplete eradication of varices and thromboembolic events for EVO, while data suggest that B-RTO may aggravate esophageal varices.
The aim of this pilot study is to evaluate the efficacy and safety of combined and simultaneous endoscopic variceal obliteration together with (modified) B-RTO. Stopping the outflow of gastric varices by endovascular balloon occlusion may allow better endoscopic visualization, blood stagnation and thus eradication of varices, while preventing thromboembolic events. Furthermore, during study follow-up, the eradication rates and recurrence of varices, short-term and long term complications, effects of the procedure on portal pressures/hemodynamics and liver function will be evaluated.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
- Informed Consent as documented by signature (Appendix "Fiche d'information aux patients et formulaire de consentement éclairé")
- Patients with endoscopically proven high-risk (diameter >2 cm, mosaic gastropathy, red spots or signs of previous bleeding) and GOV2, IGV1 and IGV2 type of gastric varices (according to Sarin classification)
- Portal hypertension secondary to cirrhosis
- Age >18
- Acute gastric or esophageal varice bleeding
- GOV1 varices according to Sarin classification
- Hemodynamic instability
- Uncompensated cirrhosis
- Contraindication to general anesthesia
- Contraindication to CT-scan/angiography (impaired kidney function, allergy to iodine based contrast)
- Allergy to cyanoacrylate, drugs or material used during procedures
- Absence of gastro-renal shunt
- Pregnancy
- Participation to another study involving ionizing radiation (dose superior to 5mSV) without direct benefice for patient during the 12 last months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Intervention arm balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices combined and simultaneous balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices
- Primary Outcome Measures
Name Time Method Gastric varice eradication following intervention (at 4 weeks) 4 weeks Gastric varice eradication following intervention (at 4 weeks) assessed by esophagogastroduodenoscopy (complete eradication or incomplete eradication)
- Secondary Outcome Measures
Name Time Method Recurrence of gastric varices 4 weeks Recurrence of gastric varices (defined as recurrence of gastric varices after complete eradication (at 4 weeks))
Effect of procedure on portal pressures 3 months Effect of procedure on portal pressures at 3 months assessed by endovascular hepatic pressure measurment (and compared with pressure before procedure).
Effect of procedure on liver function 2 years Effect of procedure on liver function and cirrhosis assessed by CHILD-PUGH score ((albumin (g/l) : \>35 = 1 point ; 28-35 = 2 points ; \<28 = 3 points); (total bilirubin (umol/l)\<34 = 1 point ; 34-50 = 2 points; \>50 = 3 points); (INR : \<1.7 = 1 point; 1.71-2.30 = 2 points; \>2.30 = 3 points), (Ascites: none = 1 point; mild = 2 points, moderate/severe= 3 points); (Hepatic Encephalopathy: none = 1 point; Grade I-II = 2 points; Grade III-IV = 3 points). Total score : 5-6 = A ; 7-9 = B; 10-15 = C.
Description of procedural complications 2 years Description of procedural complications (bleeding, pulmonary embolism)
Effect of procedure on esophageal varices 2 years Effect of procedure on esophageal varices. Classification of "Paquet" with evaluation before procedure and at 2 years after procedure (Paquet Grade 1 to 4)
Bleeding rates following procedure 2 years Bleeding rates following procedure (% of patients that had a bleeding at 2 years of follow-up following eradication and mean time to bleeding after procedure)
Description of pre-treatment variceal anatomy/classification 1 day Description of pre-treatment variceal anatomy/classification according to Sarin Classification
Gastric varice eradication following intervention 12 weeks Gastric varice eradication following intervention (at 12 weeks) assessed by esophagogastroduodenoscopy (complete eradication or incomplete eradication)